Needham & Company Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Following Positive Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: RYTM) | Delayed: 93.44 +0.87 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.57 | 52 Week High | $ | |||
| Open | $93.13 | 52 Week Low | $ | |||
| Day High | $95.35 | P/E | N/A | |||
| Day Low | $92.40 | EPS | $ | |||
| Volume | 2,003,954 | |||||
